Breast Cancer
Conference Coverage
EMBRACA shows no overall survival benefit with talazoparib
Talazoparib did not confer an overall survival benefit over chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast...
Conference Coverage
Metastatic cancer linked to worse outcomes of COVID-19
Conference Coverage
Novel combo boosts response in HER2-negative breast cancer
Article
ESMO gets creative with guidelines for breast cancer care in the COVID-19 era
Article
ASCO panel outlines cancer care challenges during COVID-19 pandemic
Article
Will coronavirus restrictions lead to more advanced cancers?
News
FDA OKs new drug for triple-negative breast cancer
Sacituzumab govitecan-hziy (Trodelvy) is now approved for adults with metastatic triple-negative breast cancer who received at least two prior...
News
‘Eye-opening’: Cognitive decline with endocrine therapy for breast cancer
News
‘Encouraging’ results with pre-op therapy for DCIS
News
European cancer centers restructure care in the era of COVID-19